Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (28437)	3/2/1999 5:05:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Actually, LGND's holy grail for farmed out areas has been SERMs, which have applications for breast cancer and osteoporosis. Today's announcement brings the number of SERMs in the clinic to four, two by PFE (Droloxifene and CP-366,156) and two by AHP (TSE424 and ERA-923). LLY has an approved SERM (Evista) and LGND is working with them on their second generation SERM. The introduction of a breast cancer SERM into the clinic has been expected, but the market could respond quite favorably because of the over-reaction to the LLY announcement. LGND in single digits is absurdly cheap.